LUC7L3 Antibody

What is LUC7L3 and why is it significant for research?

LUC7L3 (also known as CROP/CREAP-1) is the human homolog of yeast U1 small nuclear RNA (snRNA)-related splicing factor Luc7p. It functions primarily as an RNA-binding protein involved in RNA metabolism, particularly in splicing processes. The protein contains two zinc finger motifs and is localized in the nucleus with a speckled distribution .

It's particularly significant for research because:

• It plays a crucial role in preventing genomic instability

• LUC7L3 depletion impairs cell proliferation compared to other Luc7p paralogs

• It prevents R-loop accumulation, DNA replication stress, and genome instability

• It regulates spindle assembly and impacts cell division

• It's implicated in cardiac sodium channel splicing regulation with potential implications for heart failure and sudden death

What applications are validated for commercial LUC7L3 antibodies?

Current commercial LUC7L3 antibodies have been validated for multiple applications:

Most commercially available antibodies are polyclonal, rabbit-derived, and react with human, mouse, and rat samples .

How should samples be prepared for optimal LUC7L3 detection?

Sample preparation depends on the specific application:

For Western blotting:

• Prepare whole cell lysates using standard lysis buffers (RIPA or NP-40)

• Use ~30 μg of protein per lane

• Running conditions: 5-20% SDS-PAGE gel at 70V (stacking gel)/90V (resolving gel)

• Transfer to nitrocellulose membrane at 150 mA for 50-90 minutes

• Block with 5% non-fat milk/TBS for 1.5 hours at room temperature

For Immunohistochemistry:

• Heat-mediated antigen retrieval in EDTA buffer (pH 8.0) is critical

• Block with 10% goat serum

• Incubate with primary antibody (2 μg/ml) overnight at 4°C

• For secondary detection, peroxidase-conjugated anti-rabbit IgG (30 min at 37°C) works effectively

For Immunofluorescence:

• For cultured cells, enzyme antigen retrieval works well

• Block with 10% goat serum

• Compatible with multiple fluorophores (AbBy Fluor® 488, 594, 647)

What controls should be included when working with LUC7L3 antibodies?

Proper controls are essential for validating LUC7L3 antibody results:

Primary controls:

• Negative control: Isotype-matched IgG (rabbit IgG for most commercial LUC7L3 antibodies)

• Positive control tissues/cells: Brain tissue shows consistent expression; HepG2, Jurkat, HeLa, and U20S cell lines are validated positive controls

• siRNA/shRNA knockdown control: LUC7L3-depleted samples show significantly reduced signal, confirming antibody specificity

Secondary validation:

• Expected molecular weight confirmation: ~51-55 kDa band in Western blot

• Expected subcellular localization: Nuclear with speckled distribution

• Multiple antibody validation: Using antibodies targeting different epitopes of LUC7L3 to confirm findings

How can LUC7L3 antibodies be optimized for investigating its role in RNA splicing regulation?

To investigate LUC7L3's role in RNA splicing:

RNA-protein co-immunoprecipitation (RIP) protocol:

• Crosslink cells with 1% formaldehyde for 10 minutes at room temperature

• Lyse cells in buffer containing RNase inhibitors

• Immunoprecipitate with LUC7L3 antibody (4-5 μg per sample)

• Include paired IgG control

• Purify RNA from immunoprecipitated material

• Analyze bound transcripts by RT-PCR or RNA-seq

• Focus analysis on SCN5A and other potential splicing targets

Co-immunoprecipitation with splicing factors:

• LUC7L3 interacts with SRSF1, making this an important co-IP target

• Use antibodies targeting epitopes outside interaction domains

• Validate interactions with reciprocal co-IPs

• Consider combining with proximity ligation assays for in situ verification

Downstream validation:

• Compare splicing patterns between control and LUC7L3-depleted cells

• Monitor exon inclusion/skipping events

• Quantify isoform ratios using qPCR with isoform-specific primers

What methodological approaches are recommended for studying LUC7L3's role in genomic stability?

R-loop detection protocol using S9.6 antibody:

• Fix cells with 4% paraformaldehyde

• Permeabilize with 0.5% Triton X-100

• Co-stain with LUC7L3 antibody and S9.6 antibody (DNA-RNA hybrid specific)

• Image using confocal microscopy to assess co-localization

• Quantify S9.6 signal intensity as a measure of R-loop formation

DNA replication stress analysis:

• Perform DNA fiber assay in control and LUC7L3-depleted cells

• Assess replication fork progression by measuring IdU/CldU incorporation

• Monitor CHK1 phosphorylation (S345) by Western blot as a marker of replication stress

• Use LUC7L3 antibody in combination with γH2AX staining to assess DNA damage colocalization

Rescue experiments:

• Deplete endogenous LUC7L3 using siRNA/shRNA

• Express siRNA-resistant LUC7L3-GFP construct

• Express GFP-RNase H1 to resolve R-loops

• Assess rescue of genomic instability phenotypes through immunofluorescence

How can LUC7L3 antibodies be used to investigate its function in spindle assembly and cell division?

Mitotic spindle visualization protocol:

• Synchronize cells at prometaphase using nocodazole treatment

• Fix cells with cold methanol (-20°C) for 10 minutes

• Co-immunostain with LUC7L3 antibody and pericentrin (spindle pole marker)

• Add α-tubulin antibody to visualize microtubules

• Counterstain with DAPI to visualize DNA

• Image using high-resolution confocal microscopy

Quantification approaches:

• Score spindle abnormalities in control vs. LUC7L3-depleted cells

• Categorize spindle defects (multipolar, monopolar, disorganized)

• Quantify spindle pole numbers per cell

• Measure inter-pole distances

• Correlate LUC7L3 staining intensity with spindle integrity

Polysome profiling:

• Prepare polysome fractions from control and LUC7L3-depleted cells

• Isolate RNA from polysome and sub-polysome fractions

• Analyze translation efficiency of spindle-associated proteins (CEP70, CEP170, KIF2A)

• Compare with cells overexpressing SFB-LUC7L3 to confirm specificity

What considerations are important when studying LUC7L3 in cardiac disease models?

Cardiac tissue-specific protocols:

• For human heart failure samples:

  • Use paraffin-embedded sections with EDTA-based antigen retrieval

  • Extend primary antibody incubation to overnight at 4°C

  • Compare LUC7L3 expression between failing and non-failing hearts

In vitro cardiac models:

• For cardiomyocyte transfection:

  • Plate human cardiomyocytes on gelatin-coated wells (200,000 cells/well)

  • Use Fugene 6 for transfection

  • For LUC7L3 knockdown, use validated siRNAs from Santa Cruz Biotechnology

  • For overexpression, use GFP-tagged LUC7L3

Stress response analysis:

• Model stress conditions using:

  • Hypoxia treatment (1% O₂)

  • Angiotensin II treatment (200 nmol/L)

• Harvest cells at multiple time points (30 min, 24h, 48h, 72h)

• Monitor LUC7L3 expression changes by qPCR and Western blot

• Expected fold changes under hypoxia: 4.9-fold mRNA increase, 2.4-2.7-fold protein increase

• Expected fold changes under Ang II: 1.9-fold mRNA increase, 2.5-2.8-fold protein increase

Sodium channel function correlation:

• Perform whole-cell patch-clamp recording of sodium current

• Compare control, LUC7L3-depleted, and LUC7L3-overexpressing cells

• Assess SCN5A mRNA splicing using RT-PCR with primers flanking variable exons

• Note that LUC7L3-mediated abnormal SCN5A splicing can reduce Na⁺ channel current by ~91%

How can I troubleshoot non-specific binding issues with LUC7L3 antibodies?

Common sources of non-specific binding:

• Cross-reactivity with LUC7L1 and LUC7L2 (paralogs)

• Inadequate blocking

• Suboptimal antibody dilution

• Sample preparation issues

Troubleshooting strategies:

How can ChIP-seq and CLIP-seq be optimized for studying LUC7L3 DNA/RNA interactions?

CLIP-seq optimization for LUC7L3:

• Use single-end enhanced crosslinking and immunoprecipitation (seCLIP-seq) protocol

• Create epitope-tagged LUC7L3 cell lines for higher specificity

• Use input library sequences with peak height to calculate enrichment scores

• Compare binding profiles with other splicing factors from ENCODE dataset

• Focus analysis on binding motifs and positional preferences relative to splice sites

ChIP-seq considerations for LUC7L3:

• Due to LUC7L3's DNA-binding capability at cAMP regulatory elements:

  • Use formaldehyde crosslinking (1%)

  • Sonicate chromatin to 200-300bp fragments

  • Immunoprecipitate with 4-5μg antibody per sample

  • Include input and IgG controls

  • Focus analysis on cAMP regulatory element sequences

• Validate findings with:

  • EMSAs using recombinant LUC7L3

  • Reporter assays with predicted binding sites

Bioinformatic analysis approach:

• Identify enriched sequence motifs

• Map relative to transcription start sites and splice junctions

• Perform Gene Ontology analysis of bound genes

• Compare with SRSF1 binding profiles to identify shared targets

• Validate key targets using RT-PCR and qPCR